echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The findings of the Xinda BioPCSK9 antibody Tafolecimab I/II were presented at the annual meeting of the European Society of Cardiology (ESC).

    The findings of the Xinda BioPCSK9 antibody Tafolecimab I/II were presented at the annual meeting of the European Society of Cardiology (ESC).

    • Last Update: 2020-09-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    SAN FRANCISCO, U.S., August 31, 2020 -- Xinda Biopharmaceuticals (HKEx: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for major diseases such as cancer, metabolic diseases and autoimmunity, announced its announcement of PC in a wall newspaper at the 2020 Annual Meeting of the European Society of Cardiology (ESC) SK9 Recombinant All-Human Monoclonal Antibody Tafolecimab (Development Code: IBI306) For Phase I (NCT03366688) and Phase II Clinical Studies (NCT03815812) (Central European Summer Time, August 29 to September 1, 2020).
    this is the first time that the domestic PCSK9 single resistance has appeared on the international academic stage.
    the study received by the ESC was IBI306A101 and IBI306B101, which studied the safety, toerability, and pharmacodynamic characteristics of Tafolecimab in healthy subjects and patients with hypercholesterolemia, respectively, and initially explored the effectiveness.
    results show the good safety characteristics and effectiveness of Tafolecimab.
    The rate of adverse events was close among subjects receiving Tafolecimab and placebo, and LDL-C was reduced in all healthy subjects and hypercholesterolemia subjects, respectively (-52.2%, -72.1%) and (-54.30%, -72.26%).
    and compared to pcSK9 inhibitors currently available at home and abroad, Tafolecimab initially showed longer intervals, with potential dosing intervals of up to 6 or even 8 weeks.
    "Tafolecimab, as China's own innovative PCSK9 inhibitor, has better safety and tolerance in the current clinical Significant reductions in LDL-C levels have been demonstrated in the study, which will undoubtedly further benefit from reducing cardiovascular risk and provide more treatment options for patients with hypercholesterolemia in China, especially those with familial hypercholesterolemia and those with non-family hypercholesterolemia combined with high/very high risk factors.
    the early clinical results of IBI306 can be accepted and published at the ESC Annual Meeting, reflecting the innovation ability of clinical research in China has been further improved, can occupy a place in the world academic arena.
    "Although statins are currently the first choice for fat-lowering drugs, and more and more new lipid-lowering drugs have been introduced in recent years, there are still some patients who are unable to achieve treatment due to the efficacy or safety of the drugs," said Professor Cui Yimin, director of the Institute of Clinical Pharmacology at Peking University and director of the Clinical Trials Center at Peking University's First Hospital.
    PCSK9 drugs have attracted more and more attention recently because of their good efficacy and safety characteristics.
    results suggest that Tafolecimab may achieve longer intervals of administration than similar imported drugs, which will undoubtedly provide more convenience for patients with long-term treatment.
    "Tafolecimab is a class 1 bio-innovative drug developed by Xinda Bio for the treatment of hypercholesterolemia, and the results of this trial were accepted by the ESC Conference to fully reflect the innovative advantages of this molecule and its good clinical application prospects," said Dr. Qian Wei, Senior Medical Director, Department of Biomedical Sciences and Strategic Special Diseases, ESC.
    3 key registered clinical studies (CREDIT-1, CREDIT-2, CREDIT-3) are currently under way, we hope to provide doctors and patients with more personalized and convenient fat reduction options as soon as possible.
    " About Tafolecimab Tafolecimab (research and development code: IBI306) is an all-human monoclonal antibody developed by Cinda Bio for the treatment of hypercholesterolemia with anti-pre-protein conversion enzyme oxalolysis 9 (PCSK9).
    PCSK9 prevents LDL-R separation by binding to the LDL-R/LDL-C complex, making it degraded with LDL-C and cannot be recycled back to the surface of the liver cells.
    as the expression of LDL-R on the cell surface decreases, the level of LDL-C in the blood increases.
    Tafolecimab targets PCSK9, which reduces LDL-C levels by inhibiting its binding to LDL-R on the surface of liver cells and maintaining the expression of LDL-R on the surface of liver cells.
    clinical studies have initially found that Tafolecimab has good safety, tolerance and efficacy, and may achieve long intervals of dosing, giving patients better choices.
    on CIBI306A101/CIBI306B101 Study IBI306A101 and IBI306B101, respectively, in healthy subjects and patients with hypercholesterolemia to study the safety, tolerance, recommended dose and pharmacodynamic characteristics, and explore its initial effectiveness data.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.